Abbott Laboratory's RX ACCULINK Carotid Stent System outweighs its risks and patients with symptomatic and asymptomatic carotid artery diseases at standard surgical risk should be included in its usage, an FDA (Food and Drug Administration) Advisory Committee voted today; 7 in favor, 3 against and 1 abstention. At the moment, the stent is only approved for use with symptomatic and asymptomatic patients at high risk of adverse events from surgery (carotid endarterectomy). The Advisory Committee's (The Panel's) recommendation is not binding...
More...
More...